

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of diagnosis, surgery or therapy wherein an invasive device is inserted into a human or non human animal body and placed in the region in need of treatment and an MR image of at least a part of said body containing said device is generated to visualise said device, comprising the step of providing via the invasive device a therapeutically active compound and via or within the invasive device an MR medium comprising a hyperpolarised solid or solution of a hyperpolarised high T1 agent comprising nuclei selected from the group consisting of ^{19}F , ^6Li , ^{13}C , ^{15}N , ^{29}Si , ^{31}P , ^{77}Se , ^{111}Cd , ^{113}Cd , ^{115}Sn , ^{117}Sn , ^{119}Sn , ^{123}Te , ^{125}Te , ^{171}Yb , ^{195}Pt , ^{199}Hg , ^{203}Tl , ^{205}Tl and ^{207}Pb and having a T1 value of at least 5 seconds at a field strength of 0.001-5 T and a temperature of 20-40 °C.
2. (Previously presented) The method as claimed in claim 1, wherein said high T1 agent comprises nuclei selected from the group consisting of ^{13}C , ^{15}N , ^{19}F , ^{29}Si and ^{31}P nuclei.
3. (Previously presented) The method as claimed in claim 1, wherein said high T1 agent comprises nuclei selected from the group consisting of ^{13}C and ^{15}N nuclei.
4. (Previously presented) The method as claimed in claim 1, wherein said high T1 agent has a T1 value of at least 10 seconds or more, preferably 30 seconds or more, more preferably 60 seconds or more and most preferably of more than 100 seconds at a field strength of 0.001-5 T and a temperature of 20-40 °C.
5. (Currently Amended) The method as claimed in claim 1, wherein, if the MR medium is provided within the invasive device, said device contains a cavity for holding the

MR contrast medium wherein -the cavity is preferably fitted with an outside duct for facilitating circulation and addition of the MR contrast medium.

6. (Previously presented) The method as claimed in claim 1, wherein said invasive device is made from a medium conductive material containing carbon fibre.
7. (Previously presented) The method as claimed in claim 1, wherein the invasive device is inserted into a tissue and/or vasculature of the human or non-human animal body.
8. (Currently Amended) The method as claimed in claim 42, wherein the high T1 agent is the contrast medium additionally is a therapeutically active compound medium.
9. (Canceled).
10. (Canceled).
11. (Canceled).
12. (Canceled).
13. (Currently Amended) The method as claimed in claim 1, wherein the method is a method of therapy by ablation-a method for diagnosis and optional surgery on tumours.
14. (Canceled).
15. (Canceled).
16. (Canceled).
17. (Canceled).

18. (Canceled).
19. (Canceled).
20. (Canceled).
21. (New) The method as claimed in claim 8, wherein the high T1 agent is F-uracil, a receptor targeting drug, a bactericide or a fungicide.
22. (New) The method as claimed in claim 1, wherein said method is used for the destruction of solid tumors.
23. (New) The method as claimed in claim 1, wherein said high T1 agent comprises nuclei selected from the group consisting of ^{13}C , ^{15}N , ^{19}F , ^{29}Si and ^{31}P nuclei.
24. (New) The method as claimed in claim 1, wherein the high T1 agent is the therapeutically active compound and is a chemical substance effective in ablation.
25. (New) The method as claimed in claim 24, wherein said chemical substance is a carboxylic acid or an alcohol.
26. (New) The method as claimed in claim 24 wherein said chemical substance is ^{13}C -enriched ethanol.